Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tueger, S
Right arrow Articles by Kazmi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tueger, S
Right arrow Articles by Kazmi, M.
Haematologica, Vol 91, Issue 6_Suppl, ECR16-ECR16
Copyright © 2006 by Ferrata Storti Foundation

Case Reports

Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT

S Tueger, FE Chen, G Ahsan, V McDonald, VE Andrews, JA Madrigal, and MA Kazmi

Dept. of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.

Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.